137 related articles for article (PubMed ID: 36467021)
1. Effectiveness of SB4 Transition from Originator Etanercept in Rheumatoid Arthritis and Axial Spondyloarthritis: A Subgroup Analysis from the BENEFIT Study.
Luciano N; Fusaro E; Ditto MC; Ianniello A; Bellis E; Bruni C; Viapiana O; Gremese E; Migliore A; Romoli E; Conforti L; Govoni M; Matucci-Cerinic M; Selmi C
Rheumatol Immunol Res; 2022 Mar; 3(1):31-37. PubMed ID: 36467021
[TBL] [Abstract][Full Text] [Related]
2. BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis.
Selmi C; Krüger K; Cantagrel A; Abad Hernández MA; Freudensprung U; Farouk Rezk M; Addison J
Clin Exp Rheumatol; 2021; 39(2):365-371. PubMed ID: 32662409
[TBL] [Abstract][Full Text] [Related]
3. Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data.
Yoo WH; Kang YM; Kim DW; Kang EH; Lee YA; Suh CH; Sung YK; Lee SH; Gu DH; Lee J; Choe JY
Rheumatol Ther; 2023 Apr; 10(2):329-341. PubMed ID: 36482248
[TBL] [Abstract][Full Text] [Related]
4. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
[TBL] [Abstract][Full Text] [Related]
5. Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study.
Pope J; Hall S; Bombardier C; Haraoui B; Jones G; Naik L; Etzel CJ; Ramey DR; Infante R; Miguelez M; Falcao S; Sahakian S; Wu D
Adv Ther; 2022 Nov; 39(11):5259-5273. PubMed ID: 36136243
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of biosimilar infliximab CT-P13 compared to originator infliximab in biological-naïve patients with rheumatoid arthritis and axial spondyloarthritis: data from the Portuguese Register.
Marona J; Sepriano A; Ramiro S; Almeida D; Brites L; Couto M; Cunha I; Fernandes BM; Garcia J; Melo AT; Nóvoa T; Oliveira M; Pinto P; Santos MJ; Silva C; Fonseca JE; Araújo FC
ARP Rheumatol; 2023; 2(2):132-140. PubMed ID: 37421191
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases.
Kiltz U; Tsiami S; Baraliakos X; Andreica I; Kiefer D; Braun J
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221119593. PubMed ID: 36051634
[TBL] [Abstract][Full Text] [Related]
8. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
Glintborg B; Loft AG; Omerovic E; Hendricks O; Linauskas A; Espesen J; Danebod K; Jensen DV; Nordin H; Dalgaard EB; Chrysidis S; Kristensen S; Raun JL; Lindegaard H; Manilo N; Jakobsen SH; Hansen IMJ; Dalsgaard Pedersen D; Sørensen IJ; Andersen LS; Grydehøj J; Mehnert F; Krogh NS; Hetland ML
Ann Rheum Dis; 2019 Feb; 78(2):192-200. PubMed ID: 30396903
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway.
Haugeberg G; Bakland G; Rødevand E; Hansen IJW; Diamantopoulos A; Pripp AH
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1986-1995. PubMed ID: 36722450
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
[TBL] [Abstract][Full Text] [Related]
11. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases.
Bruni C; Gentileschi S; Pacini G; Baldi C; Capassoni M; Tofani L; Bardelli M; Cometi L; Cantarini L; Nacci F; Vietri M; Bartoli F; Fiori G; Frediani B; Matucci-Cerinic M
Ther Adv Musculoskelet Dis; 2020; 12():1759720X20964031. PubMed ID: 33133246
[TBL] [Abstract][Full Text] [Related]
12. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
Tarallo M; Onishchenko K; Alexopoulos ST
J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
[No Abstract] [Full Text] [Related]
13. Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial.
Proft F; Weiß A; Torgutalp M; Protopopov M; Rodriguez VR; Haibel H; Behmer O; Sieper J; Poddubnyy D
Ther Adv Musculoskelet Dis; 2021; 13():1759720X20987700. PubMed ID: 33796155
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study.
Dejaco C; Mueller T; Zamani O; Kurtz U; Egger S; Resch-Passini J; Totzauer A; Yazdani-Biuki B; Schwingenschloegl T; Peichl P; Kraus A; Naerr GW
Front Med (Lausanne); 2022; 9():881943. PubMed ID: 35721062
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data.
Atzeni F; Gerratana E; Bongiovanni S; Talotta R; Miceli G; Salaffi F; Sarzi-Puttini P
Isr Med Assoc J; 2021 Jun; 23(6):344-349. PubMed ID: 34155846
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study.
Parisi S; Becciolini A; Ditto MC; Rozza D; Zanetti A; Laganà A; Peroni CL; Centanaro Di Vittorio C; Degiovanni R; Realmuto C; Scirè CA; Priora M; Di Donato E; Santilli D; Mozzani F; Lucchini G; Ariani A; Gardelli L; Girelli F; Arrigoni E; Platè I; Bravi E; Paroli M; Caccavale R; Salvarani C; Sandri G; Lumetti F; Volpe A; Marchetta A; Fusaro E
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160074
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort.
Codreanu C; Popescu CC; Mogoșan C; Enache L; Daia S; Ionescu R; Opriș-Belinski D
Biologicals; 2019 Nov; 62():27-32. PubMed ID: 31668853
[TBL] [Abstract][Full Text] [Related]
18. Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 RA patients: A matched-analysis of the BSRBR-RA.
Kearsley-Fleet L; Rokad A; Tsoi MF; Zhao SS; Lunt M; Watson KD; ; Hyrich KL
Rheumatology (Oxford); 2023 Sep; ():. PubMed ID: 37672014
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study.
Ramonda R; Lorenzin M; Sole Chimenti M; D'Angelo S; Marchesoni A; Salvarani C; Lubrano E; Costa L; Dal Bosco Y; Fracassi E; Ortolan A; Ferraioli M; Carriero A; Visalli E; Bixio R; Desiati F; Bergamini A; Pedrollo E; Doria A; Foti R; Carletto A
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221090310. PubMed ID: 35510168
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.
Bonifati C; De Felice C; Lora V; Morrone A; Graceffa D
J Dermatolog Treat; 2020 Nov; 31(7):687-691. PubMed ID: 30985223
[No Abstract] [Full Text] [Related]
[Next] [New Search]
